Polymeric Silver Nanoparticles: Potential for Folate-Targeted Delivery of Cisplatin In Vitro

Nanotechnology is a favorable avenue for improving therapeutic strategies, especially in cancer therapy. The harmful side effects of traditional cancer therapy impact dramatically on the patient's quality of life. Cisplatin, a commonly used anticancer drug, is implicated in side effects such as neurotoxicity, nephrotoxicity and reduced blood cell count. Silver nanoparticles (AgNPs) have been investigated for their antibacterial effects and their anticancer activities to a lesser extent. Their capability as drug delivery vehicles has not been fully exploited, primarily due to their inconclusive cytotoxicity observed in healthy tissues. This study aimed to synthesize and characterize nanoparticles (NPs), consisting of Ag, chitosan (Cs) and folic acid (FA) (CsAg and FACsAg), loading them with cisplatin (C) (C-CsAg and C-FACsAg) and comparing their anticancer activities in the human embryonic kidney (HEK293), breast adenocarcinoma (MCF-7) and cervical carcinoma (HeLa) cells. All NPs and drug nanocomplexes were morphologically and physicochemically characterized, revealing NPs and nanocomplexes of favorable sizes (<110nm), polydispersity and stability. The drug encapsulation efficiencies for C-CsAg and C-FACsAg were 50% and 72%, respectively, while drug release studies indicated that cisplatin release was pH dependent. The C-FACsAg nanocomplexes produced greater anticancer activity than C-CsAg. Folate receptor-mediated uptake was confirmed for the C-FACsAg nanocomplexes in the receptor-rich HeLa cells boding well for future in vivo research.